Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 13/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19240224 | 0.91 | SLC22A12 (0.59) | SLC22A12CYP11B1CYP11B2 | |
| SCHEMBL22938888 | 0.89 | SLC22A12 (0.53) | SLC22A12CYP11B1CYP11B2 | |
| SCHEMBL17540682 | 0.88 | SLC22A12 (0.45) | SLC22A12KDM4EL3MBTL1KCNA5 | |
| Darbinurad SCHEMBL17540573 | 0.88 | SLC22A12 (0.72) | SLC22A12 | |
| Darbinurad SCHEMBL31687456 | 0.88 | SLC22A12 (0.72) | SLC22A12 | |
| Darbinurad SCHEMBL21408205 | 0.87 | SLC22A12 (0.70) | SLC22A12 | |
| SCHEMBL18978870 | 0.87 | SLC22A12 (0.59) | SLC22A12 | |
| Darbinurad SCHEMBL21408193 | 0.86 | SLC22A12 (0.58) | SLC22A12 | |
| Darbinurad SCHEMBL29677364 | 0.86 | SLC22A12 (0.58) | SLC22A12 | |
| Darbinurad SCHEMBL21408206 | 0.86 | SLC22A12 (0.58) | SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774733-B1 | NOVEL SALT FORMS OF URAT-1 INHIBITORS | INVENTISBIO CO LTD (CN) | 2025-09-24 | — | — | EP | disclosed |
| US-11685720-B2 | Salt forms of URAT-1 inhibitors | InventisBio Co., Ltd. (CN) | 2023-06-27 | — | — | US | disclosed |
| US-11685720-B2 | Salt forms of URAT-1 inhibitors | InventisBio Co., Ltd. (CN) | 2023-06-27 | — | — | US | disclosed |
| US-11685720-B2 | Salt forms of URAT-1 inhibitors | InventisBio Co., Ltd. (CN) | 2023-06-27 | — | — | US | disclosed |
| EP-3181557-B1 | CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | INVENTISBIO CO LTD (CN) | 2023-03-01 | — | — | EP | disclosed |
| US-20220371996-A1 | NOVEL SALT FORMS OF URAT-1 INHIBITORS | InventisBio Co., Ltd. (CN) | 2022-11-24 | — | — | US | disclosed |
| US-11339127-B2 | Salt forms of URAT-1 inhibitors | InventisBio Co., Ltd. (CN) | 2022-05-24 | — | — | US | disclosed |
| US-11339127-B2 | Salt forms of URAT-1 inhibitors | InventisBio Co., Ltd. (CN) | 2022-05-24 | — | — | US | disclosed |
| CN-106573908-B | Carboxylic acid compound, and preparation method and use thereof | 益方生物科技(上海)股份有限公司 | 2021-02-05 | — | — | CN | disclosed |
| US-20210032204-A1 | NOVEL SALT FORMS OF URAT-1 INHIBITORS | InventisBio Co., Ltd. (CN) | 2021-02-04 | — | — | US | disclosed |
| US-20180022736-A1 | CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | InventisBio Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
| US-9856239-B1 | Carboxylic acid compound, method for preparation thereof, and use thereof | INVENTISBIO SHANGHAI LTD. (CN) | 2018-01-02 | — | — | US | disclosed |
| US-9856239-B1 | Carboxylic acid compound, method for preparation thereof, and use thereof | INVENTISBIO SHANGHAI LTD. (CN) | 2018-01-02 | — | — | US | disclosed |
| US-9809580-B2 | Carboxylic acid compound, method for preparation thereof, and use thereof | INVENTISBIO SHANGHAI LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-9809580-B2 | Carboxylic acid compound, method for preparation thereof, and use thereof | INVENTISBIO SHANGHAI LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-9809580-B2 | Carboxylic acid compound, method for preparation thereof, and use thereof | INVENTISBIO SHANGHAI LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-20170233376-A1 | CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | InventisBio Co., Ltd. (CN) | 2017-08-17 | — | — | US | disclosed |
| US-20170233376-A1 | CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | InventisBio Co., Ltd. (CN) | 2017-08-17 | — | — | US | disclosed |
| US-20170233376-A1 | CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | InventisBio Co., Ltd. (CN) | 2017-08-17 | — | — | US | disclosed |
| EP-3181557-A1 | CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | Shanghai Shaletech Technology Co., Ltd. (CN) | 2017-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220371996-A1 | NOVEL SALT FORMS OF URAT-1 INHIBITORS | SLC5A1, SLC34A1, SLC10A1 | SLC22A12 304/4885KDM4E 2929/4885L3MBTL1 1325/4885 |
| US-20170233376-A1 | CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | CA7, CYP2C9, CA9 | SLC22A12 251/4885KDM4E 2447/4885L3MBTL1 4840/4885 |
| US-11339127-B2 | Salt forms of URAT-1 inhibitors | SLC5A1, SLC34A1, SLC10A1 | SLC22A12 365/4885KDM4E 3054/4885L3MBTL1 1280/4885 |
| US-20210032204-A1 | NOVEL SALT FORMS OF URAT-1 INHIBITORS | SLC5A1, SLC34A1, SLC10A1 | SLC22A12 304/4885KDM4E 2929/4885L3MBTL1 1325/4885 |
| US-20180022736-A1 | CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | CA7, CYP2C9, CA9 | SLC22A12 251/4885KDM4E 2447/4885L3MBTL1 4840/4885 |
| US-11685720-B2 | Salt forms of URAT-1 inhibitors | SLC5A1, SLC34A1, SLC10A1 | SLC22A12 365/4885KDM4E 3054/4885L3MBTL1 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.